Early trial explores HBM1020 for Hard-to-Treat cancers
Disease control
Completed
This early-phase study tested a new drug called HBM1020 in 17 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the right dose. The study did not aim to cure the cancer, but to see if the dr…
Phase: PHASE1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control
Last updated May 17, 2026 02:33 UTC